Sanofi Terminates MOBILIZE Phase 3 Study Of Riliprubart In Chronic Inflammatory Demyelinating Polyneuropathy, Flags No Safety Signals, No Financial Impact

뉴스 본문을 불러오고 있어요.

Sanofi Terminates MOBILIZE Phase 3 Study Of Riliprubart In Chronic Inflammatory Demyelinating Polyneuropathy, Flags No Safety Signals, No Financial Impact | 웨이프 WAPE

Sanofi Terminates MOBILIZE Phase 3 Study Of Riliprubart In Chronic Inflammatory Demyelinating Polyneuropathy, Flags No Safety Signals, No Financial Impact

기사 요약

관련 종목

댓글 —